The Long Non-Coding RNA SAMMSON Is a Regulator of Chemosensitivity and Metabolic Orientation in MCF-7

Charlotte Orre1, Xavier Dieu1,2, Jordan Guillon3

  • 1Mitolab Team, Inserm U1083, CNRS 6015, Mito Vasc Institute, SFR ICAT, Angers University, F-49000 Angers, France.

Biology
|November 27, 2021
PubMed

Insights

Long non-coding RNA SAMMSON promotes breast cancer chemoresistance by altering cell metabolism. Silencing SAMMSON in resistant cells restored sensitivity and improved oxidative metabolism, suggesting SAMMSON as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Breast cancer treatment faces challenges with tumor relapse and chemoresistance.
  • Cancer cells exhibit metabolic plasticity, aiding adaptation to therapy and microenvironment.
  • Long non-coding RNAs (lncRNAs) are emerging as key regulators of cellular metabolism.

Purpose of the Study:

  • To investigate the role of the lncRNA SAMMSON in metabolic reprogramming.
  • To determine SAMMSON's impact on doxorubicin resistance in breast cancer cells (MCF-7dox).
  • To explore SAMMSON as a potential therapeutic target for overcoming chemoresistance.

Main Methods:

  • Overexpression analysis of SAMMSON in doxorubicin-resistant MCF-7dox cells compared to sensitive MCF-7 cells.
  • Silencing of SAMMSON using small interfering RNA (siRNA) in MCF-7dox cells.
  • Assessment of metabolic changes, including oxidative metabolism and mitochondrial function.
  • Evaluation of chemoresistance levels after SAMMSON manipulation.

Main Results:

  • SAMMSON was significantly overexpressed in doxorubicin-resistant MCF-7dox cells.
  • siRNA-mediated silencing of SAMMSON led to metabolic rewiring in MCF-7dox cells.
  • Key metabolic improvements included enhanced oxidative metabolism, reduced mitochondrial reactive oxygen species (ROS), and increased mitochondrial replication, transcription, and translation.
  • Attenuation of doxorubicin resistance was observed following SAMMSON silencing.

Conclusions:

  • SAMMSON plays a critical role in the metabolic adaptations that drive chemoresistance in breast cancer.
  • Targeting SAMMSON expression offers a promising strategy to overcome doxorubicin resistance.
  • Modulating SAMMSON could be a novel therapeutic approach for breast cancer patients experiencing treatment failure.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
Translational Regulation01:29

Translational Regulation

Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
258
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
69.4K